The latest alliance is for a Phase III clinical programme of AbbVie’s upadacitinib in systemic lupus erythematosus patients. Credit: corn ratchane corn / Shutterstock.com.

AbbVie has announced a collaboration with Lupus Therapeutics to increase clinical trial recruitment activities in its systemic lupus erythematosus (SLE) trial. 

The alliance is intended for the Phase III clinical programme of AbbVie’s upadacitinib (RINVOQ) in SLE patients. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the collaboration, Lupus Therapeutics will offer assistance to AbbVie for the recruitment of trial subjects, as well as the activation and engagement of trial sites via the Lupus Clinical Investigators Network (LuCIN).

LuCIN comprises various academic centres in the North American region.

Based on Phase II trial data, AbbVie commenced the Phase III study of upadacitinib in SLE earlier this year. 

The Phase III SELECT-SLE programme of upadacitinib in SLE patients comprises two trials. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These studies will assess the safety and effectiveness of once-a-day oral upadacitinib tablets versus a placebo, along with standard-of-care background therapy.

A long-term extension will follow these studies, the company noted. 

Upadacitinib works by hindering specific signals within the inflammation-causing cells of the body. 

It is currently approved for seven immune-mediated ailments in the US and is not indicated for SLE treatment. 

Lupus Therapeutics executive vice-president Stacie Bell said: “The collaboration between Lupus Therapeutics and AbbVie will tap into the expertise of clinical researchers in the Lupus Clinical Investigators Network to help facilitate and improve the clinical trial process in the evaluation of upadacitinib in SLE. 

“Our aim is to accelerate the development of much-needed potential treatment options for SLE, allowing people with lupus to live better lives.”